Patient P-02414

Synthetic patientMETA-24 · Day 173 · 35–44 · F · baseline S13Open companion preview

Therapy response

Stable

Tolerance

Improving

GI state

Deteriorating

Inflammatory state

Favorable

Nutritional resilience

Favorable

Discontinuation risk

38%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S13
Day 15 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 22 HY-01 recommended — Hydration Protocol HY-01
Day 23 Patient accepted — Started HY-01 in the companion
Day 27 GI symptom burden −23% vs expected — Hydration Protocol HY-01
Day 33 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 15.

Primary contributors, last 14 days

GI instability+17
Toxicity-14
Inflammatory activity+4
Nutritional resilience-2
Treatment adherence+2

What helped?

Hydration Protocol HY-01Day 22
Result: symptom burden −23%

LIFE OS recommendation

Dosing / Timing Recommendation DT-01

53%

probability of meaningful tolerance improvement

284 similar trajectories
75% showed improvement
median effect visible after 5 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↑60
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- WearableHRV 32 ms, trending down
Mucosal barrier integrity ↓40
- DNAFUT2 non-secretor lowers mucosal fucosylation
- WearableSleep 5.0 h, below personal baseline
Butyrate / short-chain fatty acid production ↓35
- MicrobiomeButyrate capacity 41/100
Autonomic recovery ↑20
- WearableShort sleep window

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure
GLP1R rs6923761 A
Altered receptor sensitivity

Microbiome

Shannon diversity 2.1 · butyrate capacity 41/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiNormal
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 35 ms
Sleep: 6.1 h
Steps: 7,198
Resting HR: 69 bpm

Daily log: GI score 39, nutritional resilience 61, adherence 97.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Keep meals regular; three to four moderate portions spaced through the day
Include a cooked vegetable portion with each main meal
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Log the daily check-in; one line is enough
Keep the current walking rhythm
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
No additional supplements this week
Fictional demo item: continue vitamin D as before

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02485	49%	S05	HY-01	improved	63
P-02219	47%	S13	—	—	60
P-02417	47%	S18	DT-01	no change	55
P-02033	45%	S06	GI-04	improved	51
P-02126	45%	S16	DT-01	improved	59
P-02599	45%	S14	HY-01	improved	54
P-02639	45%	S08	—	—	58
P-02200	44%	S13	—	—	47
P-02150	43%	S11	HY-01	improved	45
P-02645	43%	S02	HY-01	improved	56
P-02351	42%	S16	—	—	51
P-02459	42%	S05	HY-01	improved	52